Chronic rhinosinusitis (CRS), inflammation of the paranasal sinuses and lining of the nasal cavity for 12 weeks or more, affects up to 12.5% of the U.S. population and has a significant disease burden. CRS patients visit primary care physicians twice as often as those without the disease and have five times as many prescriptions filled.
Based on national ambulatory data, rhinosinusitis accounts for more outpatient antibiotic prescriptions than any other diagnosis. The annual total direct and indirect cost of CRS exceeds $12 billion.
Sino-Nasal Outcome Test
Created in 1992 by Dr. Piccirillo, the Sino-Nasal Outcome Test (SNOT) is now used across the world as a measure of rhinosinusitis health status and quality of life.
The SNOT has been validated internationally, and cited in the literature more than 1,000 times. It is used in more than 35 countries and has been translated into more than 70 languages and dialects.
SNOT is available in 70 languages. See the list »